论文部分内容阅读
BCG免疫治疗已广泛地应用于人体癌症,常见的并发症为不适、发烧、出疹、脓肿、溃疡、淋巴结肿大和肝功异常,多出现于BCG肿瘤内注射。Sparks1978年报告BCG瘤内注射全身性感染(BCG症)的发生率为24%,患者也可死于BCG多点接种引起的过敏反应。BCG一般是能较好耐受的,危及生命的并发症较少见。作者报告8例恶性黑色素瘤患者,瘤内注射BCG后发生显著的血小板减少,其中2例发生了危及生命的血小板减少症。以前对这种并发症尚无认
BCG immunotherapy has been widely used in human cancer, common complication of discomfort, fever, rash, abscess, ulcers, lymph nodes and abnormal liver function, and more in BCG tumor injection. Sparks reported in 1978 that BCG had a 24% incidence of systemic infection (BCG disease) intrathecally and that patients could also die of an allergic reaction caused by BCG inoculation. BCG is generally well tolerated, and life-threatening complications are rare. The authors report that eight patients with malignant melanoma developed significant thrombocytopenia after intratumoral injection of BCG, with life-threatening thrombocytopenia occurring in two of the patients. There is no recognition of this complication before